Edition:
India

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

3.75USD
31 Jul 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.75
Open
--
Day's High
--
Day's Low
--
Volume
15
Avg. Vol
333,470
52-wk High
$12.51
52-wk Low
$2.55

Select another date:

Tue, Jun 30 2020

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

Zynerba's cannabis-based drug for rare genetic disorder fails study

Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

UPDATE 1-Zynerba's cannabis-based drug for rare genetic disorder fails study

June 30 Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabis-based gel Zygel was not statistically significant in improving aberrant behavior when compared to a placebo in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Pharmaceuticals Announces Top Line Results From Pivotal Connect-FX Trial Of Zygel

* ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ (CBD GEL) IN FRAGILE X SYNDROME

Zynerba's cannabis-based drug for rare genetic disorder fails study

June 30 Zynerba Pharmaceuticals Inc said on Tuesday its experimental cannabinoid gel, Zygel, did not meet main and key secondary goals of a pivotal trial in patients with a neurological disorder called Fragile X syndrome.

BRIEF-Zynerba Says Bright Trial Achieved Clinically Meaningful Improvements From Baseline

* ZYNERBA PHARMACEUTICALS ANNOUNCES POSITIVE TOP LINE RESULTS FROM EXPLORATORY OPEN LABEL PHASE 2 BRIGHT TRIAL OF ZYGEL IN AUTISM SPECTRUM DISORDER

BRIEF-Zynerba Pharmaceuticals Announces New Two-Year Data From Open Label Extension Of The Phase 2 Fab-C Trial In Patients With Fragile X

* ZYNERBA PHARMACEUTICALS ANNOUNCES NEW TWO-YEAR DATA FROM OPEN LABEL EXTENSION OF THE PHASE 2 FAB-C TRIAL IN PATIENTS WITH FRAGILE X AT 2020 AMERICAN ACADEMY OF NEUROLOGY (AAN) SCIENCE HIGHLIGHTS VIRTUAL SESSION

BRIEF-Zynerba Pharmaceuticals Reports First Quarter 2020 Results

* ZYNERBA PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

BRIEF-Zynerba Pharmaceuticals Announces The Completion Of Enrollment In The Pivotal Connect-FX Trial Of Zygel In Fragile X Syndrome

* ZYNERBA PHARMACEUTICALS ANNOUNCES THE COMPLETION OF ENROLLMENT IN THE PIVOTAL CONNECT-FX TRIAL OF ZYGEL™ IN FRAGILE X SYNDROME

Select another date: